December 5, 2016 7:19pm
… The fickle traders of the stem, cell, gene and regenerative therapy sector will turn-on investors if companies can’t sustain their pricing – news needed and some of Popeye’s spinach
Pre-open indication’s tally: 5 hits (ADRO, AGTC, ONCE, QURE and SGMO) and 1 miss (BSTG)
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
I answer one question; in which company should investors put, keep and commit their money!
I say today what others won't, so you can do what others can't!
U.S. equities closed higher on Monday, unfazed by a key vote in Italy which led to Prime Minister Matteo Renzi's resignation which was refused to be accepted, as financials, technology and consumer discretionary stocks rose around 1%.
The NASDAQ closed UP +53.24 or +1.01% to 5,308.89 and the DOW closed UP +45.82 or +0.24% to 19,216.24.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 30/11 and 2 flats;
- The mid-day stayed positive with an A/DL of 29/10 and 4 flats;
- The closing bell was positive with A/DL of 28/11 and 4 flat;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened positive, stayed positive at the mid-day and closed positive.
- From this morning’s investor’s letter, “Coping with an alternating sector and market frothiness … how long will the upsides last as investors are anxious re erratic signals?”
The sector was up – don’t complain just hope traders don’t get itchy sell fingers on Tuesday a.m.
- Normally, the SCG&RT sector gives investors one or two ups after one, two or three downs.
Traders have provided us for the oversold to become the overbought multiple times a week and increasingly each.
- For the last two to three weeks, investors have been looking for the sector to provide us with some sustainability. The sector continues to push against resistance so be prepared for a pullback!
However, if the sector signals that we may be stuck in a corrective pullback by weeks end.
- The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.68% and closed UP +1.72% while the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +0.54%.
The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded near 12.1.
At the close …
$ Gainers included:
- Kite Pharma (KITE) +$2.86;
- bluebird bio (BLUE) +$2.40 after Friday’s +$1.10 after Thursday’s +$8.30 after Wednesday’s -$4.05 after Tuesday’s +3.75 after last Monday’s -$3.30;
- Intrexon (XON) +$1.67 after Friday’s +$0.44 after Thursday’s -$1.34 after Wednesday’s -$1.17;
- Stemline (STML) +$1.00 after Friday’s -$0.20 after Thursday’s -$3.79 after Wednesday’s +0.05;
- Aduro Biotech (ADRO) +$0.70
The biggest $ losers of the session were:
- Bellicum (BLCM) -$0.45 after Friday’s +$1.74 after Thursday’s -$0.95;
- Regenxbio (RGNX) -$0.30;
- Osiris (OSIR) -$0.21;
- Capricor (CAPR) -$0.16;
- Fate Therapeutics (FATE) -$0.12;
The downside trend reflects a pricing trend range of:
- Monday’s decliners ranged from -0.05% <JUNO> to -10.85% <OPXA> in 11 equities;
- Friday’s decliners ranged from -0.66% <MESO> to -20.87% <ISCO>in 15 equities;
- Thursday’s decliners ranged from -0.41% <KITE> to -9.58% <ONCE> in 30 equities;
- Wednesday’s decliners ranged from -0.17% <OSIR> to -11.12% <FCSC> in 36 equities;
- Tuesday’s decliners ranged from -0.13% <XON> to -18.75% <ISCO> in 22 equities;
- Last Monday’s decliners ranged from -0.91% <BCLI> to -9.94% <BTX> in 34 equities;
The upside shows a pricing trend range of:
- Monday’s gainers ranged from +0.31% <BTX> to +26.37% <ISCO> in 28 equities;
- Friday’s gainers ranged from +0.00% <VCEL> to +10.25% <BLCM> in 25 equities;
- Thursday’s gainers ranged from +0.45% <RXGN> to 35% <BSTG> in 13 equities;
- Wednesday’s gainers ranged from +0.38% <STML> to +12.50% in 7 equities;
- Tuesday’s gainers ranged from +0.74 <CUR> to +6.18% <BLUE> in 16 equities;
- Last Monday’s gainers ranged from +1.44% <CUR> to +5.96% <ISCO> in 7 equities;
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …
- Monday’s 28 gainers followed Friday’s 25 gainers after Thursday’s 13 compared to Wednesday’s 7 following Tuesday’s 16 gainers compared to last Monday’s 7 …
- Monday’s 11 decliners following Friday’s 15 after Thursday’s 30 compared to Wednesday’s 36 decliners followed Tuesday’s 22 decliners compared to last Monday’s 34...
Pre-open indication’s tally: 5 hits (ADRO, AGTC, ONCE, QURE and SGMO) and 1 miss (BSTG)
- Aduro Biotech (ADRO) closed UP +$0.70 – hit;
- Applied Genetic Technologies (AGTC) closed UP +$0.55 – hit;
- Biostage (BSTG) closed UP +$0.04 – miss;
- uniQure (QURE) closed FLAT at $5.68 – hit;
- Sangamo (SGMO) closed FLAT at $3.10 – hit;
- Spark Therapeutics (ONCE) closed UP + UP +$0.58 – hit;
Percentage (%) decliners:
- Opexa (OPXA) +10.85%;
- Capricor (CAPR) -5%;
- Verastem (VSTM) -4.46%;
- Fate Therapeutics (FATE) -3.86% after Friday’s +2.99% after Thursday’s +2.72%;
- Osiris (OSIR) -3.70%
Percentage (%) advancers:
- International Stem Cell (ISCO) +26.37% after Friday’s -20.87% after Thursday’s -8.73%;
- Stemline (STML) +8%;
- Aduro Biotech (ADRO) +6.48%;
- Applied Genetic Technologies (AGTC) +6.15%;
- Intrexon (XON) +5.91%;
Flat:
- Asterias Biotherapeutics (NYSEMKT: AST) at $4.15;
- Sangamo (SGMO) at $3.10;
- ReNeuron (RENE.L) at $2.875;
- uniQure (QURE) at $5.68;
Review my fear gauge or the CBOE Volatility Index (VIX):
· Monday traded near 12.1;
· Friday traded near 14.1;
· Thursday traded near 14.5 - traded about 8.6% higher ;
· Wednesday traded near 13;
· Tuesday traded near 12.7;
· Last Monday traded near 12.9;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
